Table 3.
IC50 values of anti-cancer drugs for pancreatic cancer cell lines
| Drug | 5-FU (μM) | GEM (nM) | IRI (μM) | OXA (μM) | PTX (nM) |
|---|---|---|---|---|---|
| OCUP-A1 | 51.1 ± 5.1 | 6.60 ± 1.4 | 5.21 ± 0.20 | 17.6 ± 0.94 | 15.7 ± 0.60 |
| OCUP-A2 | 23.8 ± 6.3 | 6.01 ± 0.60 | 1.67 ± 0.075* | 1.63 ± 0.070* | 3.63 ± 0.14* |
| Panc-1 | 24.2 ± 12 | 59.2 ± 5.5*** | 8.90 ± 0.49*** | 9.25 ± 1.4 | 27.8 ± 0.95*** |
| MIAPaCa-2 | 10.7 ± 2.4* | 24.0 ± 10*** | 15.3 ± 0.28*** | 20.1 ± 0.91** | 6.92 ± 0.14*,** |
| RWP-1 | 11.6 ± 1.8* | 4.45 ± 1.3 | 7.02 ± 0.50*** | 18.4 ± 0.88 | 3.45 ± 0.046* |
| SW1990 | 68.2 ± 15** | 92.0 ± 4.3*** | 10.5 ± 0.47*** | 72.9 ± 6.8*** | 21.3 ± 0.86*** |
5-FU 5-fluorouracil, GEM gemcitabine, IRI irinotecan, OXA oxaliplatin, PTX paclitaxel
*vs OCUP-A1; p < 0.05
**vs OCUP-A2; p < 0.05
***vs OCUP-A1 and OCUP-A2; p < 0.05